Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.
Clinical Trials Arena on MSN20h
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Gyre Therapeutics (GYRE – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback